Indaptus Therapeutics (NASDAQ:INDP) is a biopharmaceutical company dedicated to developing novel therapies that target unmet needs in the treatment of infectious diseases and oncology. By harnessing the body's own immune system, Indaptus aims to provide innovative solutions that can lead to better patient outcomes and a significant impact on current treatment paradigms. The company is focusing on advancing its pipeline of decoy therapeutics, which are designed to engage and activate the immune response against cancer cells and pathogens. One of the main objectives of Indaptus is to bring these promising therapies through clinical trials and, ultimately, to patients in need, demonstrating their commitment to improving health and transforming lives through scientific innovation.